Orforglipron Phase 2 trial (NCT05048719)
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 383
- actual
- Start
- 15 Sep 2021 (actual)
- Primary completion
- 30 Sep 2022 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| 3 milligrams (mg) LY3502970 | Experimental | Drug: LY3502970 | Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD). |
| 12 mg LY3502970 | Experimental | Drug: LY3502970 | Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD. |
| 24 mg LY3502970 | Experimental | Drug: LY3502970 | Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD. |
| 36 mg LY3502970 - 1 | Experimental | Drug: LY3502970 | Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD. |
| 36 mg LY3502970 - 2 | Experimental | Drug: LY3502970 | Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD. |
| 45 mg LY3502970 - 1 | Experimental | Drug: LY3502970 | Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD. |
| 45 mg LY3502970 - 2 | Experimental | Drug: LY3502970 | Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD. |
| 1.5 mg Dulaglutide | Active comparator | Drug: Dulaglutide | Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW). |
| Placebo | Placebo comparator | Drug: Placebo | Participants received matching placebo. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Change From Baseline in HbA1c in LY3502970 as Compared to Placebo | Baseline, Week 26 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide | Baseline, Week 26 |
| Percentage of Participants With HbA1c ≤ 6.5% | Week 26 |
| Percentage of Participants With HbA1c <7.0% | Week 26 |
| Change From Baseline in Fasting Serum Glucose | Baseline, Week 26 |
| Change From Baseline in Body Weight | Baseline, Week 26 |
| Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970 | Pre-dose (Week (wk) 0, wk 8, wk 12, and wk 26); Post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment). |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05048719.
The oral orforglipron type 2 diabetes dose-response study
Adults with type 2 diabetes were randomised 5:5:5:5:5:3:3:3:3 to placebo, dulaglutide 1.5 mg weekly, or daily orforglipron at 3, 12, 24, 36 or 45 mg, with two escalation regimens tested for 36 mg and 45 mg.[2]
At week 26, HbA1c fell by up to 2.10% with orforglipron against 0.43% with placebo and 1.10% with dulaglutide.[2]
Bodyweight fell by up to 10.1 kg with orforglipron, versus 2.2 kg with placebo and 3.9 kg with dulaglutide.[2]
Treatment-emergent adverse events occurred in 61.8% to 88.9% of orforglipron recipients, with gastrointestinal events at 44.1% to 70.4%.[2]
Sources
- 1A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes MellitusClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) · 2023PMID 37369232Accessed 2 Oct 2026
Found an error? Report a correction.